Provided by Parkinson & Movement Disorder Alliance

The course will review previous reliable practices while bringing in new research and new medications in combination to give patients the best relief possible from these chronic neurological diseases.

Estimated time to complete activity: 85 minutes

Target Audience

This course is for movement disorder specialists, neurologists, advanced practice providers, and other healthcare professionals involved in the care of patients with a movement or related disorder.

Educational Objectives

After completing this activity, the participant should be better able to:

• Discuss ET and PD medications and their mechanisms of action
• Analyze recent clinical studies demonstrating the benefits and limitations of pharmacological treatment options for ET and PD symptoms
• Categorize pharmacological treatment options for ET and PD symptoms
• Appraise treatment algorithms for ET and PD symptoms
• Apply the gold standard pharmacologic treatments for ET and PD symptoms

Faculty

Clarisse Goas, NP
The Ohio State University Wexner Medical Center

Clarisse Goas, APRN-CNP is a Nurse Practitioner who graduated Summa Cum Laude with Research Distinction from The Ohio State University in 2008 with a Bachelor of Science in Psychology. She graduated in 2012 with her MSN in Adult Health after receiving the Health Resources and Services Administration (HRSA) Award. She worked for 4 years at Pickaway Health Services in Primary Care. Her father’s diagnosis of Parkinson’s disease contributed to her desire to subspecialize in Movement Disorders. She worked for 4 years at Wake Forest Baptist Health treating Movement Disorders patients. She returned to Ohio in 2019 and joined The Ohio State University Wexner Medical Center in the Advanced Therapies Movement Disorders program in January of 2020. She has experience in clinical trials, (both as the principal investigator and co-investigator) including new medication symptomatic interventions, deep brain stimulation (Medtronic, Boston Scientific, Abbott) and intestinal pump drug delivery systems. She currently runs the virtual quarterly PD patient education series “Understanding the Disease,” is the PD Multidisciplinary Clinic Coordinator at OSU and the NP team lead for Duopa.  

Disclosure of Relevant Financial Relationships

Parkinson and Movement Disorder Alliance (PMD Alliance) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  PMD Alliance is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

• Clarisse Goas, NP
• Principal or site investigator for research supported by Prilenia Therapeutics

Planners reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

• Britt Stone, MD
• Consultant or advisory board for Boston Scientific

• No disclosures to report

PMD Alliance has received non-CME educational funding and support from ineligible companies.  This support is not tied to continuing medical education.  These relationships have been mitigated and do not influence CME content.

All identified relevant financial relationships are thoroughly vetted and mitigated according to PMD Alliance CME Program standard operating procedures. 

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by PMD Alliance.  PMD Alliance is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physician Continuing Medical Education

PMD Alliance designates this course for a maximum of 1.5 AMA PRA Category 1 Credit(s)™.  

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Request for Credit

In order to obtain your CME certificate, please follow the directions provided at the conclusion of the course.  

If you have questions regarding the certification of this activity, please contact PMD Alliance at education@pmdalliance.org